Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GlaxoSmithKline Plc receives positive CHMP opinion for Incruse for the treatment of COPD

Friday, 21 Feb 2014 02:00am EST 

GlaxoSmithKline Plc:European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for umeclidinium under the proposed brand name Incruse.Says Incruse as a once-daily, maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.Says umeclidinium is an investigational long-acting muscarinic antagonist (LAMA).Says the proposed strength is 55mcg inhalation powder contained in the Ellipta. 

Company Quote

5 May 2015